GlassScriptPhysician profile
Clay Thomas Reed
NPI 1841721438
$8,906.69
in general payments reported to CMS, 2019-2025
19 companies · $6,671 in 2025
The $6,671 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $84.03 · 2024: $2,151 · 2025: $6,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,500 · Long Term Medical Supply Or Device Loan: $2,097 · Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,500.00 |
| Long Term Medical Supply Or Device Loan | $2,096.66 |
| Food and Beverage | $1,310.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,030.91 | 2024-2025 | Enhertu, Breztri, Calquence |
| Novartis Pharmaceuticals Corporation | $2,242.26 | 2023-2025 | |
| Caris Mpi, INC. | $105.57 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $75.39 | 2024 | |
| Eisai INC. | $72.08 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $55.01 | 2024 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $47.80 | 2023-2024 | Enhertu |
| Celgene Corporation | $42.92 | 2024 | Pomalyst |
| Incyte Corporation | $40.29 | 2024 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $34.55 | 2024 | Opdivo |
| Janssen Biotech, INC. | $34.31 | 2023-2024 | Darzalex, Tecvayli |
| Beone Medicines USA, INC. | $24.30 | 2025 | Brukinsa |
| Genmab U.S., INC. | $16.74 | 2024 | Epkinly |
| Karyopharm Therapeutics INC. | $16.50 | 2024 | Xpovio |
| Abbvie INC. | $15.35 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $15.35 | 2024 | Sylvant |
| Progenics Pharmaceuticals, INC. | $14.91 | 2024 | |
| Puma Biotechnology, INC. | $14.69 | 2024 | |
| Rigel Pharmaceuticals, INC. | $7.76 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.